Cost of illness in patients with metastatic colorectal cancer.
Cost of illness in patients with metastatic colorectal cancer.
复制标题
DOI：
10.3111/13696998.2010.536870
复制
发表时间：
2011-01-01
影响因子：
2.4
通讯作者：
Gao, Sue
中科院分区：
文献类型：
--
作者：
Song, Xue;Zhao, Zhongyun;Gao, Sue
目的：估计总成本和转移性结直肠癌（mCRC）相关的成本，并评估主要的成本驱动因素治疗新诊断的mCRC患者后，引入生物therapy.METHODS：使用一个大型的国家索赔数据库，mCRC患者的成本估计在2004-2009年通过检查（1）mCRC患者和他们匹配的非癌症队列之间的成本差异，（2）mCRC相关的成本。费用按疾病阶段（诊断、治疗和死亡）进一步评估。生存分析技术被用来估计处理可变长度的后续行动和数据censoring.Results的成本：总共有6,746例mCRC患者符合所有的合格标准，其中6,675例匹配的患者没有癌症。在疾病的三个阶段中，治疗阶段最长（16.4个月）。与匹配的非癌症患者相比，mCRC患者的每月总费用高出14，585美元，这是由于住院（7，546美元）和门诊（6，749美元）护理费用较高所致（p
OBJECTIVES: To estimate total costs and metastatic colorectal cancer (mCRC)-related costs and assess primary cost drivers of treating newly diagnosed mCRC patients after the introduction of biologic therapies.METHODS: Using a large national claims database, costs of mCRC patients were estimated in 2004-2009 by examining (1) the cost difference between mCRC patient and their matched non-cancer cohorts, and (2) mCRC-related costs. Costs were further assessed by phase of disease (diagnostic, treatment, and death). The survival analysis technique was used to estimate cost of handling variable length of follow-up and data censoring.RESULTS: A total of 6,746 mCRC patients met all eligibility criteria, 6,675 of them were matched to patients without cancer. Among the three phases of disease, the treatment phase was the longest (16.4 months). Compared with matched patients with no cancer, total monthly costs were $14,585 higher for mCRC patients, which was driven by higher inpatient ($7,546) and outpatient ($6,749) care (p